Hummingbird Bioscience Revenue and Competitors

Location

$150M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Hummingbird Bioscience's estimated annual revenue is currently $20M per year.(i)
  • Hummingbird Bioscience's estimated revenue per employee is $155,000
  • Hummingbird Bioscience's total funding is $150M.

Employee Data

  • Hummingbird Bioscience has 129 Employees.(i)
  • Hummingbird Bioscience grew their employee count by -16% last year.

Hummingbird Bioscience's People

NameTitleEmail/Phone
1
Chief Business OfficerReveal Email/Phone
2
CSO, Co-FounderReveal Email/Phone
3
Head Regulatory ScienceReveal Email/Phone
4
VP Program DevelopmentReveal Email/Phone
5
VP Antibody-Drug ConjugatesReveal Email/Phone
6
VP, Head Human ResourcesReveal Email/Phone
7
Head Mouse GeneticsReveal Email/Phone
8
VP, Target Biology and PharmacologyReveal Email/Phone
9
VP Discovery and Research PlatformsReveal Email/Phone
10
Head ProductionReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.9M63-24%$15MN/A
#2
$20M129-16%$150MN/A
#3
$3.7M48-6%$53MN/A
#4
$5.4M35-8%N/AN/A
#5
$3.6M23-18%N/AN/A
#6
$3.4M220%N/AN/A
#7
$5.4M356%N/AN/A
#8
$7.1M46-26%N/AN/A
#9
$36.1M2334%N/AN/A
#10
$3.1M20-61%N/AN/A
Add Company

What Is Hummingbird Bioscience?

Hummingbird Bioscience is an innovative clinical-stage biotech company focused on developing revolutionary therapies against hard-to-drug targets for improved treatment outcomes. We harness the latest advances in systems biology and data science to better understand and solve the underlying causes of disease and guide development of our therapeutics. Enabled by our proprietary Rational Antibody Discovery platform, we discover antibodies against optimal yet elusive epitopes on important targets that have not been successfully drugged, unlocking novel mechanisms of action. We are advancing a rich pipeline of first- and best-in-class drug candidates in oncology, autoimmune and infectious diseases, in collaboration with global partners in academia and industry. Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development. Together we aim to accelerate the journey of new drugs from concept to clinical care. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird on LinkedIn and Twitter (@hummingbirdbio).

keywords:N/A

$150M

Total Funding

129

Number of Employees

$20M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Hummingbird Bioscience News

2022-02-22 - Hummingbird Bioscience Publishes Preclinical Data Demonstrating ...

Hummingbird Bioscience is a clinical-stage biotechnology company with a proprietary Rational Antibody Discovery (RAD) platform, developing a...

2021-09-13 - Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors

HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a P ...

2021-08-02 - Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers

HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved t ...

2021-07-12 - Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies

HOUSTON and SINGAPORE, July 12, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outcomes, and The University of Texas MD Anderson Cancer C ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.1M129N/AN/A
#2
$16.8M129-23%N/A
#3
$46.2M131-2%N/A
#4
$7.5M1328%N/A
#5
$33.1M1328%N/A